Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Transplantation
Volume 2015, Article ID 801082, 3 pages
http://dx.doi.org/10.1155/2015/801082
Case Report

Treatment of Recurrent Posttransplant Lymphoproliferative Disorder with Autologous Blood Stem Cell Transplant

1Department of Internal Medicine, University of Kansas School of Medicine-Wichita, 1010 N. Kansas Street, Wichita, KS 67214, USA
2Heartland Cardiology, Heartland West, 9000 W. Central, Wichita, KS 67212, USA
3Cancer Center of Kansas, 818 N. Emporia, No. 403, Wichita, KS 67214, USA

Received 4 August 2015; Revised 13 October 2015; Accepted 5 November 2015

Academic Editor: Mohammed Rafique Moosa

Copyright © 2015 Bharat Malhotra et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Végso, M. Hajdu, and A. Sebestyén, “Lymphoproliferative disorders after solid organ transplantation-classification, incidence, risk factors, early detection and treatment options,” Pathology and Oncology Research, vol. 17, no. 3, pp. 443–454, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Parker, K. Bowles, J. A. Bradley et al., “Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipient—BCSH and BTS Guidelines,” British Journal of Haematology, vol. 149, no. 5, pp. 693–705, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. P. P. Carbone, H. S. Kaplan, K. Musshoff, D. W. Smithers, and M. Tubiana, “Report of the committee on Hodgkin's disease staging classification.,” Cancer Research, vol. 31, no. 11, pp. 1860–1861, 1971. View at Google Scholar · View at Scopus
  4. J. E. Murray, R. E. Wilson, N. L. Tilney et al., “Five years' experience in renal transplantation with immunosuppressive drugs: survival, function, complications, and the role of lymphocyte depletion by thoracic duct fistula,” Annals of Surgery, vol. 168, no. 3, pp. 416–435, 1968. View at Publisher · View at Google Scholar · View at Scopus
  5. S. H. Swerdlow, S. A. Webber, A. Chadburn, and J. A. Ferry, “Post-transplant lymphoproliferative disorders,” in WHO Classification of Tumors of Haematopoietic and Lymphoid Tissue, pp. 343–353, IARC, Lyon, France, 2008. View at Google Scholar
  6. D. W. Hanto, “Classification of Epstein-Barr virus—associated posttransplant lymphoproliferative diseases: implications for understanding their pathogenesis and developing rational treatment strategies,” Annual Review of Medicine, vol. 46, pp. 381–394, 1995. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Haque, G. M. Wilkie, M. M. Jones et al., “Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial,” Blood, vol. 110, no. 4, pp. 1123–1131, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Philip, F. Chauvin, J. Armitage et al., “Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation,” Blood, vol. 77, no. 7, pp. 1587–1592, 1991. View at Google Scholar · View at Scopus
  9. T. Philip, C. Guglielmi, A. Hagenbeek et al., “Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma,” The New England Journal of Medicine, vol. 333, no. 23, pp. 1540–1545, 1995. View at Publisher · View at Google Scholar · View at Scopus
  10. The Criteria Committee of the New York Heart Association, Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels, Little, Brown and Company, Boston, Mass, USA, 9th edition, 1994.
  11. M. E. Billingham, N. R. Cary, M. E. Hammond et al., “A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. The International Society for Heart Transplantation,” The Journal of Heart Transplantation, vol. 9, no. 6, pp. 587–593, 1990. View at Google Scholar
  12. G. L. Winters, C. C. Marboe, and M. E. Billingham, “The international society for heart and lung transplantation grading system for heart transplant biopsy specimens: clarification and commentary,” Journal of Heart and Lung Transplantation, vol. 17, no. 8, pp. 754–760, 1998. View at Google Scholar · View at Scopus
  13. S. Stewart, G. L. Winters, M. C. Fishbein et al., “Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection,” Journal of Heart and Lung Transplantation, vol. 24, no. 11, pp. 1710–1720, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. G. L. Winters, E. Loh, and F. J. Schoen, “Natural history of focal moderate cardiac allograft rejection. Is treatment warranted?” Circulation, vol. 91, no. 7, pp. 1975–1980, 1995. View at Publisher · View at Google Scholar · View at Scopus
  15. J.-J. Lloveras, G. Escourrou, M. B. Delisle et al., “Evolution of untreated mild rejection in heart transplant recipients,” Journal of Heart and Lung Transplantation, vol. 11, no. 4, part 1, pp. 751–756, 1992. View at Google Scholar · View at Scopus